Methionine aminopeptidase-2 regulates human mesothelioma cell survival - Role of bcl-2 expression and telomerase activity

被引:71
作者
Catalano, A
Romano, M
Robuffo, I
Strizzi, L
Procopio, A
机构
[1] Univ Ancona, Dept Expt Pathol, Ancona, Italy
[2] Univ Messina, Dept Human Pathol, Messina, Italy
[3] CNR, Inst Normal & Pathol Cytomorphol, Chieti, Italy
[4] Univ G DAnnunzio, Dept Oncol & Neurosci, Clin Pathol Sect, Chieti, Italy
关键词
D O I
10.1016/S0002-9440(10)61743-9
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Methionine aminopeptidase-2 (MetAP2) is the molecular target of the angiogenesis inhibitors, famagillin and ovalacin. Fumagillin can also inhibit cancer cell proliferation, implying that MetAP2 may play a quite complex role in tumor progression. Here, we examined the expression and function of MetAP2 in an in vitro model of human mesothelioma. We found that mesothelioma cells expressed higher MetAP2 mRNA levels than primary normal mesothelial cells. Consistently, fumagillin induced apoptosis, owing to early mitochondrial damage, in malignant, but not in normal mesothelial cells. Transfection of mesothelioma cells with a MetAP2 anti-sense oligonucleotide determined a time-dependent inhibition of cell survival and induced nucleosome formation. Interestingly, mRNA and protein levels of the anti-apoptotic gene bcl-2 as well as telomerase activity were selectively reduced after MetAP2 inhibition in mesothelioma cells, whereas bcl-2 overexpression counteracted the effect of MetAP2 inhibition on telomerase activity and apoptosis. MetAP2 inhibition also increased caspase activity and the caspase inhibitor, zVAD-fmk, prevented fumagillin-induced apoptosis, but it did not alter telomerase activity. These results indicate that MetAP2 is a main regulator of proliferative and apoptotic pathways in mesothelioma cells and suggest that MetAP2 inhibition may represent a potential target for therapeutic intervention in human mesothelioma.
引用
收藏
页码:721 / 731
页数:11
相关论文
共 35 条
  • [1] Phenotypic alterations of small cell lung carcinoma induced by different levels of wild-type p53 expression
    Adachi, J
    Ookawa, K
    Kohno, T
    Tomizawa, Y
    Tsuchida, S
    Yokota, J
    [J]. CELL DEATH AND DIFFERENTIATION, 1998, 5 (02) : 148 - 155
  • [2] The Bcl-2 protein family: Arbiters of cell survival
    Adams, JM
    Cory, S
    [J]. SCIENCE, 1998, 281 (5381) : 1322 - 1326
  • [3] EUKARYOTIC METHIONYL AMINOPEPTIDASES - 2 CLASSES OF COBALT-DEPENDENT ENZYMES
    ARFIN, SM
    KENDALL, RL
    HALL, L
    WEAVER, LH
    STEWART, AE
    MATTHEWS, BW
    BRADSHAW, RA
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (17) : 7714 - 7718
  • [4] BENNETT CF, 1992, MOL PHARMACOL, V41, P1023
  • [5] Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity
    Bocchetta, M
    Di Resta, I
    Powers, A
    Fresco, R
    Tosolini, A
    Testa, JR
    Pass, HI
    Rizzo, P
    Carbone, M
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (18) : 10214 - 10219
  • [6] Carbone M, 1996, ONCOGENE, V13, P527
  • [7] Simian virus-40 large-T antigen binds p53 in human mesotheliomas
    Carbone, M
    Rizzo, P
    Grimley, PM
    Procopio, A
    Mew, DJY
    Shridhar, V
    DeBartolomeis, A
    Esposito, V
    Giuliano, MT
    Steinberg, SM
    Levine, AS
    Giordano, A
    Pass, HI
    [J]. NATURE MEDICINE, 1997, 3 (08) : 908 - 912
  • [8] Fumagillin analog in the treatment of Kaposi's sarcoma: A phase I AIDS Clinical Trial Group Study
    Dezube, BJ
    Von Roenn, JH
    Holden-Wiltse, J
    Cheung, TW
    Remick, SC
    Cooley, TP
    Moore, J
    Sommadossi, JP
    Shriver, SL
    Suckow, CW
    Gill, PS
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1444 - 1449
  • [9] Dhaene K, 2000, J PATHOL, V190, P80
  • [10] Effects of TNF-α/colchicine combined treatment on Burkitt lymphoma cells:: Molecular and ultrastructural changes
    Di Pietro, R
    Robuffo, I
    Pucci, AM
    Bosco, D
    Santavenere, E
    [J]. CYTOKINE, 1999, 11 (02) : 144 - 150